The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study

Chathuri Yatawara, Fatin Zahra Zailan, Esther Vanessa Chua, Linda Lay Hoon Lim, Eveline Franco da Silva, Joanna Sihan Wang, Adeline Su Lyn Ng, Kok Pin Ng, Nagaendran KandiahClinical 2021 · DOI

Abstract

Our findings suggest that Rivastigmine may have a role in the management of patients having AD and concomitant mild-severe svCVD, with minimal side effects.
BibTeX
@inproceedings{yatawara2021efficacy,
  author = {Chathuri Yatawara and Fatin Zahra Zailan and Esther Vanessa Chua and Linda Lay Hoon Lim and Eveline Franco da Silva and Joanna Sihan Wang and Adeline Su Lyn Ng and Kok Pin Ng and Nagaendran Kandiah},
  title = {{The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study}},
  booktitle = {Clinical},
  year = {2021},
  doi = {10.2147/cia.s290055},
}

Loading related content...

Figure